Sponsored by
Latest
Topics
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Featured
IPOs
7 CFO Tips for Taking Your Company Public
Before an IPO, or any capital raise, the most crucial question the CFO will be asked is, "Are we ready?" said Flywire CFO Mike Ellis.
By
Vincent Ryan
| May 23, 2022
Read More
Resources
CFO Live
Sign Up
Menu
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Explore
Search
Latest
Resources
CFO Live
Sign Up
Sponsored by
EpiPen
Risk & Compliance
Mylan Settles Charges With SEC
Regulators said the pharmaceutical company failed to make disclosures around the DOJ’s investigation of its EpiPen.
By
Lauren Muskett
| September 27, 2019
Read More
M&A
Pfizer and Mylan to Combine Off-Patent Drugs Businesses
The combined company, which will sell Mylan’s EpiPen and Pfizer’s Viagra, could draw annual sales of more than $20 billion.
By
Lauren Muskett
| July 29, 2019
Read More
Risk & Compliance
Mylan Underpaid U.S. on Rebates for EpiPen
A federal official says the drugmaker misclassified EpiPen, possibly costing Medicaid millions of dollars in rebates.
By
Matthew Heller
| October 6, 2016
Read More
Risk
Mylan to Pay 92% Premium for Sweden’s Meda
After a relentless pursuit, pharmaceutical firm Mylan pays a large premium to acquire a company that sells over-the-counter drugs.
By
Matthew Heller
| February 11, 2016
Read More